Table 1. Gastric necrotic area percent and MPO in the INDO Group (Control) and in the Bio-Indo treated one.
It is already proved that chronic administration of non-steroidal anti-inflammatory drugs (NSAIDs) produce multiple small intestine erosions (SI) with a higher prevalence in the terminal ileum (1).This new condition is called NSAIDs induced enteropathy. In long term NSAIDs administration studies, almost 60 to 70% of patients were diagnosed through endoscopic capsules as bearing an asymptomatic enteropathy (2); characterized by increased intestinal permeability and mild mucosa inflammation, with hypoalbuminemia and deficient iron anemia(3). It was hypothesized that NSAIDs could act as liposoluble acids interacting with superficial membrane phospholipids, inducing a direct damage on the enterocyte mitochondria during the absorption. The mitochondrial damage could lead to an intracellular energy depletion, calcium efflux and generation of free radicals. The intercellular integrity is disrupted increasing the intestinal permeability, thus making the enterocytes more vulnerable in the lumen content, such as bacteria, bile, enzymes and neutrophile activation (5).
In this hypothesis no prostaglandins are effective, where the NSAIDs COX-1/ COX-2 inhibitors produce gastrointestinal necrosis (6) besides, we were able to prove that COX-3 inhibition with paracetamol simultaneously with COX-1, produce multiple erosions in the small intestine (7), and that paracetamol aggravated the intestinal erosions produced by diclofenac (8). Anyway, the selective COX-1, COX-2 or COX-3 inhibition does not produce gastrointestinal lesions (9).
bioflora is a well known probiotic containing 4 bacteria, i.e.,
2. Material and methods
Randomized female Sprague-Dawley rats groups (n=10 each one), 200g, 24h fast, water ad libitum, avoiding coprophagy were submitted to the following experiments: I. 30 mg/kg Indo, SC each12h; 2 days (control). II. 1 ml Bio (1,3x107 live bacteria), by orogastric gavage in bolus each 12h for 2 days and Indo. The rats were sacrificed by ether overdose, performing laparatomy, total gastrectomy and enterectomy, stomach aperture and small intestine to tabulate the macroscopic necrotic percentage by computerized planimetry. The number of intestinal erosions (mm2) was quantified, obtaining gastric and intestinal mucosa samples for histochemical examination (myeloperoxydase (MPO)). Bacteriological cultures were performed on mesenteric lymph nodes. Four cm terminal ileum was removed to quantified CD4+ T lymphocytes utilizing immunohistochemical techniques; anti-rat human antibody (Dakko, USA) evaluating each sample through Madsen scale. (13)
Percentage of macroscopic gastric lesional area is presented in table 1, demonstrating that the Bio-Indo Group provided a marked gastric mucosa protection (p<0.001), and MPO showed also a decrease of neutrophile infiltrate (p<0.02).
In table 2, are shown the erosive intestinal area were Bioflora avoid the occurrence of Indo induced erosions (p<0.01) and MPO reverted also the neutrophile infiltrate.
In table 3 can be observed the significant decrease of the intestinal bacterial overgrowth produced by Bio (p<0.01), as well as the bacterial translocation to the intestinal mesenteric lymph nodes (p<0.02) and the immunohistochemistry of the ileum mucosa. Bio restored the immunity showing a marked increase of T lymphocytes (CD4+). (Figure 1).
Our results confirmed that the NSAIDs such as Indo produced marked decrease of small intestine immunity due T lymphocytes (CD 4+) effect, that might lead to a secondary bacterial overgrowth, intestinal bacterial translocation with altered intestinal permeability and finally occurrence of intestinal erosions. This could lead to a new hypothesis since the increase of T (CD4+) that impede the bacterial overgrowth and the neutrophile infiltration might protect the defensive barrier avoiding the onset of NSAID enteropathy.
Reuter (14), demonstrated the importance of the enteropathic circulation of NSAIDs, where sulindac, without effect, does not produce a damage to the small intestine; there could be also altered absorption of biliary salts by NSAIDs, and which is most important, loss of integrity of COX-1 and COX-2 (15).
The cycloxygenase inhibition could affect the blood flow of intestinal villi, since it was observed microvascular injury in the jejunal villi as a previous event to the erosion occurrence (16). The eNOS could be administered associated with NSAIDs, since it provides gastrointestinal protection, but not INOS that aggravates ulceration. (17, 18)
Misoprostol in high doses showed a mild increase of the intestinal permeability to Indo (19) although other works do not show such effect (20). Metronidazol that attenuate the intestinal inflammation and hemorrhage was also studied, although it did not modified the intestinal permeability (24). Sulphasalazine was also evaluated showing a slight improvement of the intestinal permeability (22).
There is important to differentiate the NSAIDs induced enteropathy from others such as the one produced in the espondiloarthrosis, especially if NSAIDs are administered, in Crohn's disease (23). Patients with NSAIDs enteropathy must suppress as a first option NSAIDs, since the disease could persist up to a year after therapy discontinuation (24) and any kind of NSAIDs is forbidden, COX-2 included (25) except in patients with chronic joint pain and gastroduodenal ulcer risk that could be treated with naproxen, without cardiovascular risks and with a proton pump blocker such as esomeprazol (26).Briefly, NSAIDs enteropathy presents in its physiopathology a similarity with Chron's disease (27), although attenuated, where the theory of the inflammatory intestinal disease is actually an immunodeficiency with bacteria proliferation on the intestinal mucosa crypts and penetration of the intestinal defensive barrier. This observation Is supported by the fact that a-defensines production is not correlated with the disease severity(28); finally in the NSAIDs mucosa enteropathy a good defense of the intestinal mucosa to avoid bacterial penetration is to treat immunodeficiency, through probiotics prescription Live bacteria could theoretically prevent the damage induced by NSAIDs altering the microbial alteration induced by NSAIDs in the intestinal microbial ecology (30) and by immune function modulation (31). Anyway there were different probiotics that exacerbated the intestinal ulceration, confirmed with the same model of induced Indomethacin enteropathy (32). The Bioflora probiotic provided a marked protection of the gastrointestinal mucosa in the same indomethacin model. The efficacy of the drugs under study, probiotics included, depends also on the inhibition of the pro-inflammatory cytokines activated by the TLR4/D88 mediators, that are important in the intestinal pathology of Crohn's disease and NSAIDs enteropathy development (33, 34).
We postulated that NSAID induced lesion in stomach and small intestine, by two mechanism different, in stomach the NSAID inhibited both COX1 and COX2 and provokes depletion of Prostaglandins and gastric necrosis; in contrast, the NSAID in small intestine produced marked decrease of the immunity due T Lymphocytes (CD4T) effect, that lead to a secondary bacterial permeability with the neutrophile infiltration in mucosa intestinal and formation of mesenteric lymph nodes; besides, the inhibition COX3 induce multiple erosions in small intestine. The cyclooxygenase inhibition affect the blood flow of intestinal villi as a previous event to the erosions occurrence. The Probiotics its increased T lymphocytes (CD4T), inhibited the bacterial overgrowth, the neutrophiles, the bacterial translocation and erosions in all the small intestine.
|% gastric necrotic area||MPO mg / protein|
|INDO||65 ±7 P||410 ±31 P|
|BIO-INDO||7.5 ±1.3 < 0.001||30 ±7 <0.01|
|Erosions in SI mm2||MPO mg / protein|
|INDO||380 ±31 P||435 ± 45 P|
|BIO-INDO||41 ± 6 <0.001||55 ± 11 <0.001|
|SI Culture CFU||Mesenteric lymph node cultures||CD4+ Ileum|
|INDO||7,5 ±3,5 x1010||P||9 (+) 1 (-)||P||0,5 ±0.1||P|
|BIO-INDO||2,3 ±0,8 x 105||<0.01||8 (-) 2 (-)||<|
|4 ± 1||<|
Is nosteroidal anti-inflammatory drug. (NSAID) enteropathy clinically more important than NSAID gastropathy? Postgrad Med y Adebayo Bjamason. I. 2006 82 186 191
Side-effects of NSAIDs on the small and large intestine in humans. Gastroenterology Bjamason I. Haylar . Macpherson A. J. AS Russell 1993 104 1832 1847
Blood and protein loss via small intestinal inflammation induced by NSAIDs. Lancet Bjamason I. Zanelli Prouse. P. et al. 1987 2 711 714
Somasundaram S. Simpson R. J. Watts J. et al. Indomethacin – Induced Enteropathy and Its Prevention with the Probiotic Bioflora in RatsAliment Pharmacol Therap 2000 14 639 650
Gastroenterology Bjamason I. Zanelli G. Smith T. et al. N. S. A. I. D. drug induced. inflammation in. humans 1987 93 480 489
Wallace J. L. Mc Knight W. Reuter B. K. et al. N. S. A. I. Indomethacin – Induced Enteropathy and Its Prevention with the Probiotic Bioflora in Rats
Laudanno OM. COX.The trends in COX.2 Inhibitory Research Editor: Maynard J Howardell. Nova Science Publisher, Inc. 1- COX.2 simultaneous inhibitory mechanism in gastric injury and COX.2- COX.3 in small intestine injury. 2006Chapter 3. 41-46.
Paracetamol amplifica las erosiones intestinales inducidas por Diclofenac, en ratas. Mecanismo COX-3. Laudanno O. M. San Miguel. P. Cesolari J. 2002Arg Gasfroent pg 9 (GP- 033).
AINEs inhibidores selectivos COX.1 o COX.2, sin dano gastrointestinal, en ratas. Medicina Laudanno O. M. Piombo G. Cesolari J. et al. A. I. N. 2001A).
Bioflora prevents intestine ulcers produced by Diclofenac, in rats. BIOCELL Laudanno O. M. Cesolari J. Arramberry L. et al. 2003A.
Laudanno O. M. Vasconcellos L. Catalano J. Cesolari J. Indomethacin – Induced Enteropathy and Its Prevention with the Probiotic Bioflora in RatsDig Dis Sci 2006 51 2180 2183
Laudanno O. M. Cesolari J. Godoy A. Indomethacin – Induced Enteropathy and Its Prevention with the Probiotic Bioflora in Ratsrats. Dig Dis Sci 2008
Madsen KL, Doyle JS, Jewell LD, et al.Lactobacilli species prevents colitis in interleukin 10 gene-deficient mice. Gastroenterology 1999 116 1107 1114
Reuter BK, Daries NM, Wallace JL. NSAID enteropathy in rats: role of permeability, bacteria, and enterohepatic circulation. Gastroenterology 1997 112 109 117
Gastroenterology Sigthorsson G. Simpson R. J. Walley M. C. O. X. X. C. O. intestinal integrity. pathogenesis of. N. S. A. I. D-enteropathy in. mice 2002 122 1913 1923
Kelly D. A. Piasecki C. Anthony A. et al. Indomethacin – Induced Enteropathy and Its Prevention with the Probiotic Bioflora in Rats
Ohno R. Yokota A. Tanaka A. et al. Indomethacin – Induced Enteropathy and Its Prevention with the Probiotic Bioflora in RatsJPharmacol Exp Ther 2004 310 821 827
Dual action of nitric oxicle in pathogenesis of indomethacin-induced small intestinal ulceration in rats. J Physiol Pharmacol Tanaka A. Kumikata T. Mizoguchi H. et al. 1999 50 405 417
Effect of prostaglandin on indomethacin induced increased intestinal permeability in man. Scand J Gastroent. Efarrnasson I. Smethust P. Clurk P. et al. 1989 164 97 112
Jorchirs RT, Hunt RH.Increased bowel permeability so (51 Cr) EDTA in con 50 is caused by repar or is not presented by cytoprotection. Arch Rheum 1998R11.
Metronidazole reduces intestinal inflammation and blood loss in NSAID-induced enteropathy. Gut Bjamason I. Smethurst P. Price A. MJ Gumpel 1992 33 1204 1208
Treatment of nonsteroidal anti-inflammatory drug induced enteropathy Gut Bjamason I. Zanelli G. Pyouse P. et al. 1990 31 777 780
Epidemology and diferential diagnosis of NSAID-induced injury to the mucosa of small intestine. Best Pract Res Clin Gastroenterol Smale S. Sigthorsson G. Bjamason I. 2001 15 723 738
Aliment Pharmacol Ther Laine L. Smith R. Mink et. al Systematic. review the. lower gastrointestinal. adverse effects. of nonsteroidal. anti-inflammatory drugs. 2006 24 751 767
Brophy JM. Indomethacin – Induced Enteropathy and Its Prevention with the Probiotic Bioflora in RatsCurr Opin Gastroent. 2007 23 6 617 624
Am J Gastroent. Chan F. K. L. The David. Y. Graham Lecture. Use of. Nonsteroidal Antiinflammatory. Drugs in. a. C. O. X. Restricted Environment. 2008 103 1 221 227
Fortum PJ, Hawkey CJ.Non steroidal inflammatory drug and the small intestine. Curr Opin Gastroent. 2007 23 134 141
Gut Wehkamp J. Harder J. Weichenthal M. et al. N. O. D. . C. A. R. D. 1. mutations in. Crohn’s disease. are associated. with diminished. mucosal alfa-defensin. expression 2004 53 1658 1664
Boirivant M. Strober W. Indomethacin – Induced Enteropathy and Its Prevention with the Probiotic Bioflora in RatsCurr Open Gastroent 2007 23 679 692
Collins MD, Gibson GR. Probiotics, prebiotic and symbiotics: approaches for modulating the microbial ecology of the gut.Am J Clin Nutr 1999 69 10525 10527S.
Erick KL, Hubbard NE.Probiotics immunomodulation in health and disease. J Nutr 2000 21 426 430
Lactobacillusrhammonosus exacerbates intestinal ulceration in a model of indomethacin-induced enteropathy. Dig Dis Sci Amil R. MS Guer Butler. et al. 2007 57 1247 1252
Scarpignato C. N. S. A. I. D-induced intestinal. damage are luminal. bacteria the. therapeutic target?. Gut 2008 57 145 148
Wantabe T, Higuchi K, Kobala A, et al. Non-steroidal anti-inflammatory drug-induced small intestinal damage is Toll-like receptor 4 dependent. Gut 2008; 57: 181 - 187.